ClinicalTrials.gg
WithdrawnNCT02552901LFT-0002Updated Jan 15, 2016

Cardiox Liver Function Test Pivotal Trial

A Phase 3 interventional study of 0.1 mg/kg ICG Dose and 0.5 mg/kg ICG dose in Hepatic Failure and Liver Failure, sponsored by Cardiox Corporation. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-15.

Sponsored by Cardiox Corporation · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Liver Failure with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Liver Failure · United States.

Enrollment
34th of 38
0 · median 31
Started
2015
with 3 others
Phase 3
2 of 49
none open now
Registered
29th of 49
by date
Lead sponsor
1 of 49
Cardiox Corporation

Among the 49 studies in Liver Failure with a site in United States, this one is the 34th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2015, is one of 2 in phase 3, and was the 29th registered.

Liver Failure

190 studies on the registry are indexed under Liver Failure; 33 are open to participants now.

Browse Liver Failure studies →

Open to participants now

6 of the 49 studies in Liver Failure with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Liver Failure studies recruiting now, 11 (50%) set no upper age limit and 8 (36%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Liver Failure with a site in United States, or all of them as a file.
02

Study summary

Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum ICG PDR.

Read the detailed description

Indocyanine green (ICG) is a water-soluble, non-toxic tricarbocyanine dye, extracted principally by hepatic parenchymal cells and excreted almost entirely into the bile without enterohepatic circulation. Clinically, its elimination rate is used primarily to measure hepatic function and liver blood flow. ICG studies are also used in ophthalmic angiography and the determination of cardiac output.

Beginning about 1959, the first human clinical studies were reported wherein an indocyanine green (ICG) bolus was injected into a vein, and then blood samples were withdrawn over a period of time and analyzed for ICG concentrations. This method is referred to hereinafter as the serial blood sampling method. These blood samples are sent to a clinical laboratory for a multi-step process of centrifuging, separation and spectrophotometric measurements of ICG levels. The laboratory-based measured levels of residual ICG levels are then used to determine the ICG clearance rate and R15 value or residual amount of dye remaining after 15 minutes, expressed as a percentage of the initial concentration.

As an alternative to the time- and labor-consuming serial blood sampling method, a non-invasive technique was first reported nearly 20 years ago. In the first published clinical study, Ishigami reported the use of a pulse dye densitometry (PDD) method to transcutaneously detect the rate of clearance of ICG from the bloodstream to be referred to hereinafter as dynamic liver function testing.

PDD expresses ICG elimination in terms of the indocyanine green plasma disappearance rate because only relative ICG concentration changes are assessed. The results of this noninvasive method have been shown to correlate with those obtained by the invasive method used in critically ill patients (hemodynamically unstable and stable), and in patients after liver surgery.

ICG elimination rate after liver transplantation measured by either invasive or noninvasive ICG methods is widely used to evaluate graft function. Studies have shown that ICG elimination, measured on the day of transplantation, reflects graft function and can be used to predict graft viability and the expected survival of the patient. Sequential measurements of ICG elimination between days 0 and 28 of transplantation, have been shown to predict clinical outcome in the early postoperative period after living donor transplantation. All of the studies have shown that the ICG elimination rate is an accurate test for evaluating liver dysfunction, but lacks the ability to differentiate the underlying causes of the hepatic dysfunction.

Unlike all currently existing PDD methods for performing liver function testing, LFT Dye Monitor System employs a more sensitive method for the transcutaneous measurement of ICG concentration level in the blood using NIR fluorescence, with a sensor that is attached loosely to the scaphoid fossa of the ear. Thus, the chemical properties of ICG dye to fluoresce when properly excited are used in the LFT system to enable much lower concentrations of ICG to be detectable.

03

Conditions studied

  • Hepatic Failure
  • Liver Failure

Keywords

  • hepatic
  • liver
  • LFT
  • hepatic assessment
  • ICG dye
  • indocyanine green dye
  • Diagnostic Green
  • Pulsion
  • Akorn
  • Cardiox
  • anazen
  • essence
  • dye detection monitor
  • Earpads
  • flow sensor
  • scaphoid fossa
  • liver disease
  • acute hepatic failure
  • AHF
  • NASH
  • hepatitis C
  • cirrhosis
  • MELD
  • pulse dye densitometry
  • liver transplant
  • fluorescence
  • near infra-red
  • serial blood draws
  • PDR
  • plasma disappearance rate
  • R15
  • k coefficient
  • transcutaneously
  • liver donor
  • liver dysfunction
  • Child-Pugh
  • AST
  • ALT
  • GGT
  • alk phos
  • prothrombin time
  • albumin
  • serum ICG
  • liver function tests
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between 18 to 75 years of age inclusive, at the time of Screening.
  2. Voluntarily provide written .
  3. Female patients are eligible only if all of the following apply:

    • Not pregnant (negative urine pregnancy test at the Screening visit);
    • Not lactating;
    • Not planning to become pregnant within the duration of the study;
    • Surgically sterile, or at least 2 years , or is practicing an acceptable form of (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, subdermal implant, oral contraceptives, abstinence, or sterilization of monogamous partner) for greater than 60 days prior to Screening and commits to the use of the acceptable form of birth control for the duration of the study.
  4. If a healthy volunteer; is considered to be in generally good health, in the opinion of the Investigator, at the Screening visit based upon the results of their medical and surgical history, vital signs, physical examination, and clinical laboratory tests.
  5. Prior to receiving any ICG injections the subject agrees to be fasting for at least eight (8) hours.
  6. If a subject with liver cirrhosis; is considered to be in general satisfactory health, in the opinion of the Investigator (other than their hepatic impairment) at the Screening visit based upon the results of their medical and surgical history, vital signs, physical examination, and non-hepatic clinical laboratory tests.
  7. Liver cirrhosis subjects must have a clinical diagnosis of hepatic impairment based on documented evidence of hepatic cirrhosis by medical history, or previous liver , or hepatic ultrasound; which conforms to the criteria for class A or B or C of the Childs-Pugh classification (Appendix B); and are expected to require an ICG liver function study, such as for liver transplantation, liver resection, liver cirrhosis prognosis evaluation, functional liver cell mass and/or general liver dysfunction evaluations.
  8. On stable drug therapy that is not expected to change (i.e. in dose, frequency, additions or deletions of agents) for at least 2 weeks before ICG dye injection.
  9. Must, in the Investigator's opinion, be able to comply with study procedures.
  10. If the Subject is being enrolled in the fifth group they have a diagnosis of acute liver failure (ALF) as defined by the Principal Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Have any condition or unstable current illness that would, in the opinion of the Investigator, preclude study participation or interfere with the assessment of the procedure;
  2. Known allergy or sensitivity to ICG dye or history of allergy to iodides;
  3. Actively bleeding associated with acute blood volume changes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    LFT Dye Detection Monitor

    Drug: 0.1 mg/kg ICG Dose · Drug: 0.5 mg/kg ICG dose

  • Active comparator
    Serial Blood Draws

    Drug: 0.5 mg/kg ICG dose

Interventions

  • Drug0.1 mg/kg ICG Dose

    least efficacious dose

    Also known as: LFT Dose

  • Drug0.5 mg/kg ICG dose

    per package insert

06

What researchers measure

Primary outcomes

  1. plasma disappearance rate

    Time frame: Study Day 1

Secondary outcomes

  1. physical examinations

    Time frame: Study Day 1

  2. vital signs

    Time frame: Study Day 1

  3. adverse events

    Time frame: Study Day 1

07

Study locations

1 site
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2015
First posted
Sep 17, 2015
Start
Nov 2015
Primary completionEst.
May 2016
CompletionEst.
May 2016
Last update
Jan 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02552901
Lead sponsor
Cardiox Corporation
Responsible party
Sponsor
First posted
Sep 17, 2015
Start date
Nov 2015
Primary completion
May 2016 (estimated)
Completion
May 2016 (estimated)
Last update
Jan 15, 2016

Study contacts

Michael Jopling, MD
study director · Medical Director, Cardiox Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion